scholarly journals The prognostic value of age in non-metastatic gastric cancer after gastrectomy: a retrospective study in the U.S. and China

2018 ◽  
Vol 9 (7) ◽  
pp. 1188-1199 ◽  
Author(s):  
Jieyun Zhang ◽  
Lu Gan ◽  
Mi-die Xu ◽  
Mingzhu Huang ◽  
Xiaowei Zhang ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Retrospective Study ◽  
Prognostic Value ◽  
Metastatic Gastric Cancer ◽  
The U.S

The prognostic significance of IL-1-B and GST T1/M1 polymorphisms in non-metastatic gastric cancer

2006 ◽  
Vol 24 (18_suppl) ◽  
pp. 4084-4084
Author(s):  
M. S. Al-Moundhri ◽  
B. Al-Bahrani ◽  
M. Al-Nabhani ◽  
I. Burney ◽  
M. Al-Kindy ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Prognostic Value ◽  
Prognostic Significance ◽  
Stage Iv ◽  
Metastatic Gastric Cancer ◽  
Signet Ring ◽  
Distal Gastric Cancer ◽  
Gastric Cancer Patients ◽  
Pathological Stages

4084 Background: Gastric cancer is the most common malignancy in Oman. The proinflammatory cytokine IL-1-B polymorphisms have been associated with increased gastric cancer risk and shown to be of a prognostic value in advanced gastric cancer. Our aim is to study the prognostic significance of IL-1B- 31, -3954, IL-1RN- and GST T1/M1 polymorphisms in non-metastatic gastric cancer and correlate it with clinicopthological features. Methods: Genomic DNA was extracted from peripheral blood of 40 gastric cancer patients treated with adjuvant chemotherapy or chemoradiotherapy. The DNA samples were analyzed using TaqMan real-time polymerase chain reaction and 5’ nuclease assay. The deletion of GST T1/M1 genes was assessed by PCR. Results: The pathological stages were stage I = 1, stage II = 13, stage III = 22, stage IV = 3. The median follow up was 17 months. There was no prognostic significance for all the above polymorphisms in isolation. However, IL-1RN 2/2 IL-31 C/C genotypes (n = 13) were associated with worst outcome compared with IL-1RN L/L or 2/L and IL-31 T/T and T/C genotypes (n = 27). The median survival of IL-1RN 2/2 IL-31 C/C genotype was 16 months versus 63 months for IL-1RN L/L or 2/L and IL-31 T/T and T/C genotypes (p = 0.035). The IL-1RN 2/2 IL-31 C/C genotype correlated with signet ring pathology (p = 0.01) and non-distal gastric cancer location (p = 0.01). There was no significant association with T, N, or overall stage. Conclusion: These preliminary results suggest a prognostic value for IL-1-B polymorphisms in non-metastatic gastric cancer. No significant financial relationships to disclose.

scholarly journals Prognostic Value of Systemic Immune Index in Patients with Metastatic Gastric Cancer

2021 ◽  
Vol 37 (2) ◽  
pp. 95-100
Author(s):  
Hacer Demir ◽  
Yavuz Katırcılar ◽  
İsmail Beypınar ◽  
Saliha Karagöz Eren ◽  
Mevlüde İnanç
Keyword(s):  
Gastric Cancer ◽  
Prognostic Value ◽  
Metastatic Gastric Cancer

scholarly journals The Prognostic Value of Pre-treatment Hemoglobin (Hb) in Patients With Advanced or Metastatic Gastric Cancer Treated With Immunotherapy

2021 ◽  
Vol 11 ◽  
Author(s):  
Miaomiao Gou ◽  
Yong Zhang ◽  
Tiee Liu ◽  
Tongtong Qu ◽  
Haiyan Si ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Multivariate Analysis ◽  
Prognostic Value ◽  
Univariate Analysis ◽  
Objective Response ◽  
Progression Free Survival ◽  
Metastatic Gastric Cancer ◽  
Significant Prognostic Factor ◽  
Angiogenic Therapy ◽  
Pre Treatment

BackgroundBiomarkers such as prevailing PD-L1 expression and TMB have been proposed as a way of predicting the outcome of immunotherapy in patients with advanced gastric cancer (AGC) and metastatic gastric cancer (MGC). Our study aims to investigate whether there is a link between pretreatment hemoglobin (Hb) levels and survival to immunotherapy in patients with AGC and MGC.MethodsWe retrospectively reviewed patients with AGC or MGC treated at the oncology department of the Chinese PLA general hospital receiving PD-1 inhibitor. The Propensity Score Matching (PSM) (1:1) was performed to balance potential baseline confounding factors. Progression-free survival (PFS) and overall survival (OS) was analyzed among different Hb level (normal Hb group and decreased Hb group). Objective response rate (ORR), disease control rate (DCR) were also analyzed. Univariate analysis and multivariate analysis were performed further to validate the prognostic value of Hb level.ResultsWe included 137 patients with AGC and MGC who received PD-1 inhibitors (including Pembrolizumab, Nivolumab, Sintilimab, Toripalimab) in this study. After PSM matching, there were no significant differences between the two groups for baseline characteristics. Within the matched cohort, the median PFS was 7.8 months in the normal Hb level group and 4.3 months in the decreased Hb group (HR 95% CI 0.5(0.31, 0.81), P=0.004). The OS was 14.4 months with normal Hb level as compared with 8.2 months with decreased Hb level(HR 95% CI 0.59(0.37, 0.94), P=0.024). The ORR was 40.7% and DCR was 83.0% in the normal Hb group, while the ORR was 25.5% and DCR was 85.1% in the decreased Hb group. No significant differences were found in the ORR and DCR between the two groups (P=0.127, P=0.779). Univariate analysis and multivariate analysis showed that Hb level was only independent predictor for PFS and baseline Hb level was significant prognostic factor influencing the OS. Only when patients had normal Hb level, anti-pd-1 monotherapy or combined with chemotherapy was superior to anti-pd-1 plus anti-angiogenic therapy with respect to PFS (10.3 m vs 2.8 m, HR 95% CI 0.37(0.15, 0.95), P=0.031) and OS(15 m vs 5.7 m, HR 95% CI 0.21 (0.08, 0.58), P=0.001).ConclusionsOur study have demonstrated that pretreatment Hb level was an independent prognostic biomarker in term of PFS and OS with immunotherapy for AGC and MGC patients. Correction of anemia for GC patients as immunotherapy would be a strategy to improve the survival. More data was warranted to further influence this finding.

scholarly journals A Predictive Nomogram for Early Death of Metastatic Gastric Cancer: A Retrospective Study in the SEER Database and China

2020 ◽  
Vol 11 (18) ◽  
pp. 5527-5535
Author(s):  
Ying Zhu ◽  
Xiongfeng Fang ◽  
Lanqing Wang ◽  
Tao Zhang ◽  
Dandan Yu
Keyword(s):  
Gastric Cancer ◽  
Retrospective Study ◽  
Early Death ◽  
Metastatic Gastric Cancer ◽  
Seer Database

Abstract B138: Prognostic value of PTEN loss for second-line paclitaxel treatment efficacy in metastatic gastric cancer

2018 ◽  
Author(s):  
Kyoo Hyun Kim ◽  
Jeong Hyun Jo ◽  
Sejung Park ◽  
Minkyu Jung ◽  
Woo Sun Kwon ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Treatment Efficacy ◽  
Prognostic Value ◽  
Metastatic Gastric Cancer ◽  
Second Line ◽  
Pten Loss ◽  
Paclitaxel Treatment

Matrix metalloproteinase-9 (MMP-9) and vascular endothelial growth factor (VEGF) mRNA expression in patients with metastatic gastric cancer receiving first-line chemotherapy

2009 ◽  
Vol 27 (15_suppl) ◽  
pp. 4547-4547
Author(s):  
C. Pauligk ◽  
R. Wirtz ◽  
K. Steinmetz ◽  
J. T. Hartmann ◽  
N. Homann ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Overall Survival ◽  
Mrna Expression ◽  
Prognostic Value ◽  
Validation Cohort ◽  
Metastatic Gastric Cancer ◽  
Hazard Ratio ◽  
Phase Iii ◽  
Vegf Mrna ◽  
Training Cohort

4547 Background: In preclinical tumor models, VEGF and MMP-9 induced each other, resulting in the enhancement of tumor angiogenesis and the formation of metastases. This study evaluated MMP-9 and VEGF in patients (pts) with metastatic gastric cancer. Methods: Patient tumor samples from a phase III trial of the AIO were prospectively collected. VEGF and MMP-9 mRNA were isolated from paraffin embedded tissues using a new patented method based on nanotechnology. The expression was then assessed by qRT-PCR and by immunohistochemistry (IHC). Results: A total of 137 (training cohort 96; validation cohort 41) out of 220 pts enrolled were analyzed. In the training cohort, increased MMP-9 levels were strongly associated with increased VEGF expression, resistance to chemotherapy and shorter progression-free and overall survival. At the cut-off with the highest predictive value, the rate of disease progression as best response associated with elevated MMP9 expression was 50% (vs. 22.4%; Fisher's test p=.027) and median overall survival (OS) was 3.1 months (vs. 8.7 months, log rank p=.0000165). This prognostic value for survival was maintained when data were analyzed in the multivariate setting (relative hazard ratio for death 3.67, p=.00045) or were categorized according to the quartile (p=.004) or median (p=.024) distributions for MMP-9. VEGF showed a prognostic effect in pts with low MMP-9 expression, only. In the validation cohort, the prognostic value of increased MMP-9 expression could be confirmed at the best cut off derived from the training cohort, with the hazard ratio for death being 3.45 (p=.02). Interestingly, in the IHC, stromal but not tumoral MMP-9 protein expression predicted survival (log rank p=.033). Conclusions: Tumoral MMP-9 mRNA expression levels are the first validated molecular prognostic factor in metastatic gastric cancer. These results have implications for novel anti-protease/ anti-VEGF treatment strategies. [Table: see text]

scholarly journals The prognostic value of baseline hematological parameters of peripheral blood in metastatic gastric cancer treated with apatinib

2022 ◽  
Vol 13 (1) ◽  
pp. 15-20
Author(s):  
Jin-Ru Yang ◽  
Dan-Yang Zhou ◽  
Ying Wu ◽  
Ying Zhu ◽  
Zhen-Yu Lin ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Peripheral Blood ◽  
Prognostic Value ◽  
Hematological Parameters ◽  
Metastatic Gastric Cancer

scholarly journals Prognostic Value of the Nutritional Risk Screening 2002 Scale in Metastatic Gastric Cancer: A Large-Scale Cohort Study

2019 ◽  
Vol 10 (1) ◽  
pp. 112-119 ◽  
Author(s):  
Yuan-Fang Li ◽  
Run-Cong Nie ◽  
Ting Wu ◽  
Shu-Man Li ◽  
Shi Chen ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Cohort Study ◽  
Prognostic Value ◽  
Large Scale ◽  
Metastatic Gastric Cancer ◽  
Nutritional Risk ◽  
Risk Screening ◽  
Nutritional Risk Screening 2002 ◽  
Nutritional Risk Screening

scholarly journals The prognostic value of systemic inflammatory factors in patients with HER2-positive metastatic gastric cancer

2018 ◽  
Vol 29 ◽  
pp. v16
Author(s):  
N. Martínez-Lago ◽  
R. Lesta-Mellid ◽  
C. Reboredo Rendo ◽  
M. Reboredo-Lopez ◽  
L. Antón Aparicio
Keyword(s):  
Gastric Cancer ◽  
Prognostic Value ◽  
Metastatic Gastric Cancer ◽  
Inflammatory Factors ◽  
Her2 Positive
Sign in / Sign up

Export Citation Format

Share Document